Download PDF
Klin Monbl Augenheilkd 2021; 238(10): 1108-1112
DOI: 10.1055/a-1478-4248
Übersicht

Neue Antimykotika in der Pipeline – auch für die Augenheilkunde?

Eine kurze Übersicht Article in several languages: English | deutsch
Wolfgang J. Behrens-Baumann
Otto-von-Guericke-Universität Magdeburg, Emeritus, Universitätsaugenklinik, Deutschland
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Corrected by:

Erratum: Neue Antimykotika in der Pipeline – auch für die Augenheilkunde?Klin Monbl Augenheilkd eFirst
DOI: 10.1055/a-1546-6709

Zusammenfassung

Sieben neue Antimykotika werden vorgestellt, die in der Entwicklung und in den Zulassungsphasen unterschiedlich weit vorangeschritten sind. Die Substanzen stellen überwiegend neue Stoffklassen dar, aber auch Weiterentwicklungen bekannter Medikamente. Primär sind sie für die systemische Anwendung gedacht. Die intravenöse Formulierung kann möglicherweise mit Unterstützung der Klinikapotheke aber auch topisch genutzt werden. In dieser kurzen Übersicht werden die Aktivitäten gegenüber verschiedenen Pilzarten beschrieben. Bei erfolgloser konventioneller Therapie von Pilzinfektionen des Auges mag eine der neuen Substanzen geeignet sein, um die Mykose günstig zu beeinflussen.

Schlüsselwörter

Infektiologie - Mikrobiologie - Pharmakologie


Publication History

Received: 06 February 2021

Accepted: 26 March 2021

Article published online:
01 July 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References/Literatur

  • 1 Ahmed SA, Hofmüller W, Seibold M. et al. Tintelnotia, a new genus in Phaeosphaeriaceae harbouring agents of cornea and nail infections in humans. Mycoses 2017; 60: 244-253 DOI: 10.1111/myc.12588.
    CrossrefPubMedGoogle Scholar
  • 2 Habbe KJ, Frings A, Schrader S. et al. Tintelnotia destructans: ein neuer Feind vor dem Tore. Ophthalmologe 2018; 115: 948-950 DOI: 10.1007/s00347-017-0641-5.
    CrossrefPubMedGoogle Scholar
  • 3 Behrens-Baumann WJ, Hofmüller W, Tammer I. et al. Keratomycosis due to Tintelnotia destructans refractory to common therapy treated successfully with systemic and local terbinafin in combination with polyhexamethylene biguanide. Int Ophthalmol 2019; 39: 1379-1385 DOI: 10.1007/s10792-018-0930-2.
    CrossrefPubMedGoogle Scholar
  • 4 Schelenz S, Hagen F, Rhodes JL. et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control 2016; 5: 35 DOI: 10.1186/s13756-016-0132-5.
    CrossrefPubMedGoogle Scholar
  • 5 Breazzano MP, Tooley AA, Godfrey KJ. et al. Candida auris and endogenous panophthalmitis: clinical and histopathologic features. Am J Ophthalmol Case Rep 2020; 19: 100738 DOI: 10.1016/j.ajoc.2020.100738.
    CrossrefPubMedGoogle Scholar
  • 6 Trief D, Gray ST, Jacobiec FA. et al. Invasive fungal disease of the sinus and orbit: a comparison between mucormycosis and Aspergillus. Br J Ophthalmol 2016; 100: 184-188 DOI: 10.1136/bjophthalmol-2015-306945.
    CrossrefPubMedGoogle Scholar
  • 7 Bawankar P, Lahane S, Pathak P. et al. Central retinal artery occlusion as the presenting manifestation of invasive rhino-orbital-cerebral mucomycosis. Taiwan J Ophthalmol 2020; 10: 62-65 DOI: 10.4103/tjo.tjo_72_18.
    CrossrefPubMedGoogle Scholar
  • 8 Rauseo AM, Coler-Reilly A, Larson L. et al. Hope on the Horizon: Novel Fungal Treatments in Development. Open Forum Infect Dis 2020; 7: ofaa016 DOI: 10.1093/ofid/ofaa016.
    CrossrefPubMedGoogle Scholar
  • 9 Pfaller MA, Huband MD, Flamm RK. et al. In vitro activity of APX001A (Manogepix) and comparator agents against 1,706 fungal isolates collected during an international surveillance program in 2017. Antimicrob Agents Chemother 2019; 63: e00840-19 DOI: 10.1128/AAC.00840-19.
    CrossrefPubMedGoogle Scholar
  • 10 Trzoss M, Covel JA, Kapoor M. et al. Synthesis of analogs of the Gwt1 inhibitor Manogepix (APX001A) and in vitro evaluation against Cryptococcus spp. Bioorg Med Chem Lett 2019; 29: 126713 DOI: 10.1016/j.bmcl.2019.126713.
    CrossrefPubMedGoogle Scholar
  • 11 Perfect JR. The antifungal pipeline: a reality check. Nat Rev Drug Discov 2017; 16: 603-616 DOI: 10.1038/nrd.2017.46.
    CrossrefPubMedGoogle Scholar
  • 12 Lima SL, Colombo AL, Almeida JN. Fungal cell wall: emerging antifungals and drug resistance. Front Microbiol 2019; 10: 2573 DOI: 10.3389/fmicb.2019.02573.
    CrossrefPubMedGoogle Scholar
  • 13 Alkhazraji S, Gebremariam T, Alqarihi A. et al. Fosmanogepix (APX001) is effective in the treatment of immunocompromised mice infected with invasive pulmonary scedosporiopsis or disseminated fusariosis. Antimicrob Agents Chemother 2020; 64: e01735-19 DOI: 10.1128/AAC.01735-19.
    CrossrefPubMedGoogle Scholar
  • 14 Shaw KJ, Ibrahim AS. Fosmanogepix: A review of a first-in-class broad spectrum agent for the treatment of invasive fungal infections. J Fungi (Basel) 2020; 6: 239 DOI: 10.3390/jof6040239.
    CrossrefPubMedGoogle Scholar
  • 15 Wiederhold NP, Najvar LK, Shaw KJ. et al. Efficacy of delayed therapy with Fosmanogepix (APX001) in a murin model of Candida auris invasive Candidiasis. Antimicrob Agents Chemother 2019; 63: e01120-19 DOI: 10.1128/AAC.01120-19.
    CrossrefPubMedGoogle Scholar
  • 16 Gebremariam T, Alkhazraji S, Algarihi A. et al. Fosmanogepix (APX001) is effective in the treatment of pulmonary murine mucormycosis due to Rhizopus arrhizus . Antimicrob Agents Chemother 2020; 64: e00178-20 DOI: 10.1128/AAC.00178-20.
    CrossrefPubMedGoogle Scholar
  • 17 Aruanno M, Glampedakis E, Lamoth F. Echinocandins for the treatment of aspergillosis: from laboratory to bedside. Antimicrob Agents Chemother 2019; 63: e00399-19 DOI: 10.1128/AAC.00399-19.
    CrossrefPubMedGoogle Scholar
  • 18 Arendrup MC, Jørgensen KM, Hare KR. et al. In vitro activity of Ibrexafungerp (SCY-078) against Candida auris isolates as determined by EUCAST methodology and comparison with activity against C. albicans and C. glabrata and with activities of six comparator agents. Antimicrob Agents Chemother 2020; 64: e02136-19 DOI: 10.1128/AAC.02136-19.
    CrossrefPubMedGoogle Scholar
  • 19 Pfaller MA, Messer SA, Rhomberg PR. et al. Differential activity of the oral glucan synthase inhibitor SCY-078 against wild-type and echinocandin-resistant strains of Candida species. Antimicrob Agents Chemother 2017; 61: e00161-17 DOI: 10.1128/AAC.00161-17.
    CrossrefPubMedGoogle Scholar
  • 20 Gintjee T, Donnelly MA, Thompson 3rd GR. Aspiring antifungals: review of current antifungal pipeline developments. J Fungi (Basel) 2020; 6: 28 DOI: 10.3390/jof6010028.
    CrossrefPubMedGoogle Scholar
  • 21 Lamoth F, Alexander BD. Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates. Antimicrob Agents Chemother 2015; 59: 4308-4311 DOI: 10.1128/AAC.00234-15.
    CrossrefPubMedGoogle Scholar
  • 22 Larkin E, Hager C, Chandra J. et al. The emerging pathogen Candida auris: Growth phenotype, virulence factors, activity of antifungals and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation. Antimicrob Agents Chemother 2017; 61: e02396-16 DOI: 10.1128/AAC.02396-16.
    CrossrefPubMedGoogle Scholar
  • 23 Petraitis V, Petraitiene R, Katragkou A. et al. Combination therapy with Ibrexafungerp (formerly SCY-078), a first-in-class triterpenoid inhibitor (1 → 3)-β-D-glucan synthesis, and Isavuconazole for treatment of experimental invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2020; 64: e02429-19 DOI: 10.1128/AAC.02429-19.
    CrossrefPubMedGoogle Scholar
  • 24 Wring S, Borroto-Esoda K, Solon E. et al. SCY-078, a novel fungicidal agent, demonstrates distribution to tissues associated with fungal infections during mass balance studies with intravenous and oral [14C]SCY-078 in albino and pigmented rats. Antimicrob Agents Chemother 2019; 63: e02119-18 DOI: 10.1128/AAC.02119-18.
    CrossrefPubMedGoogle Scholar
  • 25 Oliver JD, Sibley GEM, Beckmann M. et al. F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. Proc Natl Acad Sci U S A 2016; 113: 12809-12814 DOI: 10.1073/pnas.1608304113.
    CrossrefPubMedGoogle Scholar
  • 26 Wiederholt NP. Review of the novel investigational antifungal olorofim. J Fungi (Basel) 2020; 6: 122 DOI: 10.3390/jof6030122.
    CrossrefPubMedGoogle Scholar
  • 27 Abe M, Nakamura S, Kinjo Y. Efficacy of T-2307, a novel arylamidine, against ocular complications of disseminated candidiasis in mice. J Antimicrob Chemother 2019; 74: 1327-1332 DOI: 10.1093/jac/dkz020.
    CrossrefPubMedGoogle Scholar
  • 28 Mroczyńska M, Brillowska-Dąbrowska A. Review on current status of echinocandins use. Antibiotics (Basel) 2020; 9: 227 DOI: 10.3390/antibiotics9050227.
    CrossrefPubMedGoogle Scholar
  • 29 Garcia-Effron G. Rezafungin – Mechanisms of action, susceptibility and resistance: Similarities and differences with other echinocandins. J Fungi (Basel) 2020; 6: 262 DOI: 10.3390/jof6040262.
    CrossrefPubMedGoogle Scholar
  • 30 Aigner M, Lass-Flörl C. Encochleated Amphotericin B: Is the oral availability of Amphotericin B finally reached?. J Fungi (Basel) 2020; 6: 66 DOI: 10.3390/jof6020066.
    CrossrefPubMedGoogle Scholar
  • 31 Roth M, Daas L, Renner-Wilde A. et al. Das Deutsche Pilzkeratitisregister: Erste Ergebnisse einer Multicenterstudie. Ophthalmologe 2019; 116: 957-966
    CrossrefPubMedGoogle Scholar
  • 32 Benson H. Permeability of the cornea to topically applied drugs. Arch Ophthalmol 1974; 91: 313-327
    CrossrefPubMedGoogle Scholar
  • 33 Vorwerk CK, Streit F, Binder L. et al. Aqueous humor concentration of voriconazole after topical administration in rabbits. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1179-1183 DOI: 10.1007/s00417-008-0849-9.
    CrossrefPubMedGoogle Scholar
  • 34 Lau D, Fedinands M, Leung L. et al. Penetration of voriconazole 1 % eyedrops into human aqueous humor. A prospective open-label study. Arch Ophthalmol 2008; 126: 343-346
    CrossrefPubMedGoogle Scholar
  • 35 Vorwerk CK, Tuchen S, Streit F. et al. Aqueous humor concentrations of topically administered caspofungin in rabbits. Ophthalmic Res 2009; 41: 102-105 DOI: 10.1159/000187627.
    CrossrefPubMedGoogle Scholar
  • 36 Behrens-Baumann W, Finis D, MacKenzie C. et al. Keratomykose – Therapiestandards und aktuelle Entwicklungen. Klin Monbl Augenheilkd 2015; 232: 754-764 DOI: 10.1055/s-0035-1546032.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Liston SD, Whitesell L, Kapoor M. et al. Enhanced efflux pump expression in Candida mutants results in decreased manogepix susceptibility. Antimicrob Agents Chemother 2020; 64: e00261-20 DOI: 10.1128/AAC.00261-20.
    CrossrefPubMedGoogle Scholar
  • 38 Song J, Zhou J, Zhang L. et al. Mitochondria-mediated azole drug resistance and fungal pathogenicity: opportunities for therapeutic development. Microorganisms 2020; 8: 1574 DOI: 10.3390/microorganisms8101574.
    CrossrefPubMedGoogle Scholar
  • 39 Doft BH, Weiskopf J, Nilsson-Ehle I. et al. Amphotericin clearance in vitrectomized versus nonvitrectomized eyes. Ophthalmology 1985; 92: 1601-1605
    CrossrefPubMedGoogle Scholar
  • 40 Hariprasad SM, Wieler WF, Holz ER. et al. Determination of vitreous, aqueous and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004; 122: 42-47
    CrossrefPubMedGoogle Scholar
  • 41 Prajna NV, Krishnan T, Rajaraman R. et al. Effect of oral voriconazole in fungal keratitis in the Mycotic Ulcer Treatment Trial (MUTT II): a randomized clinical trial. JAMA Ophthalmol 2016; 134: 1365-1372 DOI: 10.1001/jamaophthalmol.2016.4096.
    CrossrefPubMedGoogle Scholar
  • 42 Sponsel WE, Graybill JR, Nevarez HL. et al. Ocular and systemic posaconazole (SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br J Ophthalmol 2002; 86: 829-830
    CrossrefPubMedGoogle Scholar
  • 43 Tu EY, McCartney DL, Beatty RF. et al. Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592). Am J Ophthalmol 2007; 143: 222-227
    CrossrefPubMedGoogle Scholar
  • 44 Tu EY, Park AJ. Recalcitrant Beauveria bassiana keratitis: confocal microscopy findings and treatment with posaconazole (Noxafil). Cornea 2007; 26: 1008-1010
    CrossrefPubMedGoogle Scholar
  • 45 Altun A, Kurna SA, Sengor T. et al. Effectiveness of posaconazole in recalcitrant fungal keratitis resistant to conventional antifungal drugs. Case Rep Ophthalmol Med 2014; 2014: 701653 DOI: 10.1155/2014/701653.
    CrossrefPubMedGoogle Scholar
  • 46 Pleyer U, Mondino BJ, Adamu SA. et al. Immune response to Staphylococcus epidermidis-induced endophthalmitis in a rabbit model. Invest Ophthalmol Vis Sci 1992; 33: 2650-2663
    PubMedGoogle Scholar
  • 47 Behrens-Baumann W. Kortikosteroide als Additiv zur antimikrobiellen Therapie. Ophthalmologe 2016; 113: 964-965 DOI: 10.1007/s00347-016-0352-3.
    CrossrefPubMedGoogle Scholar
  • 48 Kramer A, Behrens-Baumann W. eds. Antiseptic Prophylaxis and Therapy in ocular Infections – Principles, Clinical Practice and Infection Control. Developments in Ophthalmology Vol. 33. Basel: Karger; 2002
    CrossrefGoogle Scholar
  • 49 Roth M, Steindor E, Kurzai O. et al. Mykotische Keratitis: Klinische Zeichen, Diagnose, Therapie. Augenheilkunde up2date 2020; 10: 8-16 DOI: 10.1055/a-0646-6404.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 50 Rahman MR, Johnson GJ, Husain R. et al. Randomised trial of 0,2 % chlorhexidine gluconate and 2,5 % natamycin for fungal keratitis in Bangladesh. Br J Ophthalmol 1998; 82: 919-925
    CrossrefPubMedGoogle Scholar
  • 51 Oliveira dos Santos C, Kolwijck E, van der Lee HA. et al. In vitro activity of chlorhexidine compared with seven antifungal agents against 98 Fusarium isolates recovered from fungal keratitis patients. Antimicrob Agents Chemother 2019; 63: e02669-18 DOI: 10.1128/AAC.02669-18.
    CrossrefPubMedGoogle Scholar
  • 52 Behrens-Baumann W. Keratomykose. In: Pleyer U. Hrsg. Entzündliche Augenerkrankungen. 2. Aufl.. Berlin, Heidelberg: Springer; 2021. [in press]
    Google Scholar